Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
-
Eli Lilly (NYSE: LLY) announced new global collaborations focused on ion channel drug discovery with OmniAb and a trial partnership with Amplia Therapeutics in KRAS G12C-mutant lung cancer.
-
The OmniAb agreement centers on applying its ion channel platform to Eli Lilly's neuroscience research pipeline.
-
The Amplia collaboration targets a clinical trial program that combines FAK and KRAS G12C-directed therapies for lung cancer patients.
-
These deals expand Eli Lilly's external R&D partnerships across neuroscience and oncology, adding depth to its early and mid stage pipeline.
For readers tracking how large drug makers are using partnerships and computing heavy research to reshape their pipelines, the wider trend in infrastructure that supports this kind of R&D is also worth a closer look through 56 AI infrastructure stocks .
Eli Lilly is a US-based pharmaceuticals company with a global footprint across the US, Europe, China, Japan and other markets. This provides it with a broad base of patients and research partners for areas such as neuroscience and oncology, which support these new collaborations.
3 things going right for Eli Lilly that this headline doesn't cover.
Eli Lilly partnerships push the Narrative beyond obesity drugs
The Eli Lilly Narrative is built around incretin-led growth with support from a broader specialty portfolio. These OmniAb and Amplia deals matter because they test whether Lilly can turn that story into a more balanced engine across neuroscience and oncology.
"Advancements in research and development, particularly in neurodegenerative diseases and a deep clinical pipeline with multiple late-stage readouts, position Eli Lilly to capture future multi-billion dollar market opportunities..."
Read the full Eli Lilly narrative to see the case behind these numbers
For readers, the OmniAb ion channel work lines up directly with the Narrative's emphasis on neuroscience and specialty drugs rather than only obesity. It shows Eli Lilly using its higher 2026 revenue guidance of US$85b to US$87b to support external platforms that could widen the future earnings base beyond Mounjaro and Zepbound.
The Amplia trial collaboration pulls olomorasib into a combination strategy that echoes what competitors like Merck and Amgen are doing in targeted oncology. That leans into the Narrative reward around a deep clinical pipeline, while also reinforcing the risk that heavier R&D and trial spend in a few areas can raise execution stakes if results disappoint.
For any news on Eli Lilly, the key is how it shifts the long term direction of the business, which is exactly what a clear Narrative helps you track over time. To ensure you're always in the loop on how the latest news impacts the investment narrative for Eli Lilly, head to the community page for Eli Lilly to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LLY .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
